ARCHIVES

PDQ Evaluation to Cost NCI More Than Reported

This article is from The Cancer Letter archive.

Vol. 16 No. 26 | June 29, 1990

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Anastrozole Better Than Tamoxifen For HR+ Postmenopausal Breast Cancer, Study Finds

May 27, 2005

Another HHS Recommendation: Screen 50 And Older For Colorectal Cancer;

March 15, 2002

In Brief: Control Grant Review committee Out Of Grants Division Provisional Training Announcement Due

October 10, 1975

Breslow Says NCI, Centers, States Should Collaborate On Cancer Control

June 1, 1984

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

November 28, 2008